BRPI0409733A - derivado de pirimidina, sua forma tautomérica ou estereoisomérica, ou um seu sal, éster ou pró-droga, medicamento, uso de um composto, e, processo para controlar um distúrbio ou doença associado com a atividade crth2 em humanos e animais - Google Patents
derivado de pirimidina, sua forma tautomérica ou estereoisomérica, ou um seu sal, éster ou pró-droga, medicamento, uso de um composto, e, processo para controlar um distúrbio ou doença associado com a atividade crth2 em humanos e animaisInfo
- Publication number
- BRPI0409733A BRPI0409733A BRPI0409733-5A BRPI0409733A BRPI0409733A BR PI0409733 A BRPI0409733 A BR PI0409733A BR PI0409733 A BRPI0409733 A BR PI0409733A BR PI0409733 A BRPI0409733 A BR PI0409733A
- Authority
- BR
- Brazil
- Prior art keywords
- pyrimidine derivative
- disorder
- crth2
- diseases
- activity
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 7
- 201000010099 disease Diseases 0.000 title abstract 5
- 230000000694 effects Effects 0.000 title abstract 4
- 150000003230 pyrimidines Chemical class 0.000 title abstract 3
- 150000003839 salts Chemical class 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 208000035475 disorder Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 241001465754 Metazoa Species 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 150000002148 esters Chemical class 0.000 title 1
- 239000000651 prodrug Substances 0.000 title 1
- 229940002612 prodrug Drugs 0.000 title 1
- 102000009389 Prostaglandin D receptors Human genes 0.000 abstract 2
- 108050000258 Prostaglandin D receptors Proteins 0.000 abstract 2
- 238000011282 treatment Methods 0.000 abstract 2
- 208000016557 Acute basophilic leukemia Diseases 0.000 abstract 1
- 208000032671 Allergic granulomatous angiitis Diseases 0.000 abstract 1
- 229940124003 CRTH2 antagonist Drugs 0.000 abstract 1
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 abstract 1
- 206010009900 Colitis ulcerative Diseases 0.000 abstract 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 abstract 1
- 208000011231 Crohn disease Diseases 0.000 abstract 1
- 201000004624 Dermatitis Diseases 0.000 abstract 1
- 206010012438 Dermatitis atopic Diseases 0.000 abstract 1
- 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 abstract 1
- 102000011652 Formyl peptide receptors Human genes 0.000 abstract 1
- 108010076288 Formyl peptide receptors Proteins 0.000 abstract 1
- 108091006027 G proteins Proteins 0.000 abstract 1
- 102000030782 GTP binding Human genes 0.000 abstract 1
- 108091000058 GTP-Binding Proteins 0.000 abstract 1
- 241000282412 Homo Species 0.000 abstract 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
- 208000019693 Lung disease Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical class C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 abstract 1
- 206010039085 Rhinitis allergic Diseases 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 210000004241 Th2 cell Anatomy 0.000 abstract 1
- 201000006704 Ulcerative Colitis Diseases 0.000 abstract 1
- 206010052568 Urticaria chronic Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 208000002205 allergic conjunctivitis Diseases 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 201000010105 allergic rhinitis Diseases 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 208000024998 atopic conjunctivitis Diseases 0.000 abstract 1
- 201000008937 atopic dermatitis Diseases 0.000 abstract 1
- 208000010668 atopic eczema Diseases 0.000 abstract 1
- 210000003651 basophil Anatomy 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 208000024376 chronic urticaria Diseases 0.000 abstract 1
- 210000003979 eosinophil Anatomy 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 210000000265 leukocyte Anatomy 0.000 abstract 1
- 206010024378 leukocytosis Diseases 0.000 abstract 1
- 230000000414 obstructive effect Effects 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 201000009890 sinusitis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/30—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Otolaryngology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03009384A EP1471057B1 (en) | 2003-04-25 | 2003-04-25 | Pyrimidinylacetic acid derivatives useful for the treatment of diseases mediated by CRTH2 |
| PCT/EP2004/003910 WO2004096777A1 (en) | 2003-04-25 | 2004-04-14 | Pyrimidine derivatives useful for the treatment of diseases mediated by crth2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0409733A true BRPI0409733A (pt) | 2006-05-09 |
Family
ID=32946880
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0409733-5A BRPI0409733A (pt) | 2003-04-25 | 2004-04-14 | derivado de pirimidina, sua forma tautomérica ou estereoisomérica, ou um seu sal, éster ou pró-droga, medicamento, uso de um composto, e, processo para controlar um distúrbio ou doença associado com a atividade crth2 em humanos e animais |
Country Status (32)
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0301010D0 (sv) | 2003-04-07 | 2003-04-07 | Astrazeneca Ab | Novel compounds |
| DE60303238T2 (de) | 2003-04-25 | 2006-09-14 | Actimis Pharmaceuticals, Inc., La Jolla | Pyrimidin-Essigsäure Derivate geeignet zur Behandlung von CRTH2-bedingten Krankheiten |
| SA04250253B1 (ar) | 2003-08-21 | 2009-11-10 | استرازينيكا ايه بي | احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن |
| MX361174B (es) * | 2003-12-23 | 2018-11-29 | Genentech Inc | Anticuerpos anti-il13 novedosos y sus usos. |
| DK1718649T3 (da) * | 2004-01-31 | 2009-08-24 | Actimis Pharmaceuticals Inc | Imidazo[1,2-c]pyrimidinyleddikesyrederivater |
| JP4051398B2 (ja) | 2004-03-11 | 2008-02-20 | アクテリオン ファマシューティカルズ リミテッド | テトラヒドロピリドインドール誘導体 |
| GB0415320D0 (en) | 2004-07-08 | 2004-08-11 | Astrazeneca Ab | Novel compounds |
| GB0418830D0 (en) | 2004-08-24 | 2004-09-22 | Astrazeneca Ab | Novel compounds |
| EP1817282B1 (en) | 2004-11-23 | 2011-07-20 | AstraZeneca AB | Phenoxyacetic acid derivatives useful for treating respiratory diseases |
| ATE524182T1 (de) | 2005-04-21 | 2011-09-15 | Merck Serono Sa | 2,3-substituierte pyrazinsulfonamide als crth2- hemmer |
| WO2006125784A1 (en) | 2005-05-24 | 2006-11-30 | Laboratoires Serono S.A. | Tricyclic spiro derivatives as crth2 modulators |
| DOP2006000210A (es) | 2005-10-04 | 2007-06-15 | Aventis Pharma Inc | Compuestos de pirimidina amida como inhibidores de pgds |
| EP1937632A1 (en) * | 2005-10-06 | 2008-07-02 | Astra Zeneca AB | Novel compounds |
| TW200745003A (en) | 2005-10-06 | 2007-12-16 | Astrazeneca Ab | Novel compounds |
| WO2007062677A1 (en) * | 2005-11-30 | 2007-06-07 | 7Tm Pharma A/S | Thiazolyl- and pyrimidinyl-acetic acids and their use as crth2 receptor ligands |
| WO2007143745A2 (en) * | 2006-06-09 | 2007-12-13 | Icos Corporation | Substituted phenyl acetic acids as dp-2 antagonists |
| CA2679198C (en) | 2007-02-26 | 2011-07-12 | Pfizer Products Inc. | Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases |
| US8278310B2 (en) * | 2007-06-21 | 2012-10-02 | Actimis Pharmaceuticals, Inc. | Amine salts of a CRTH2 antagonist |
| EP2170838A1 (en) * | 2007-06-21 | 2010-04-07 | Actimis Pharmaceuticals, Inc., | Particulates of a crth2 antagonist |
| UA100983C2 (ru) | 2007-07-05 | 2013-02-25 | Астразенека Аб | Бифенилоксипропановая кислота как модулятор crth2 и интермедиаты |
| KR20100061746A (ko) | 2007-09-25 | 2010-06-08 | 액티미스 파마수티컬스 인코포레이티드 | Ｃｒｔｈ２ 길항제로서의 ２－ｓ－벤질 치환된 피리미딘 |
| EP2205569B1 (en) | 2007-09-25 | 2012-02-29 | Actimis Pharmaceuticals, Inc., | Alkylthio pyrimidines as crth2 antagonists |
| US8067445B2 (en) | 2008-02-01 | 2011-11-29 | Panmira Pharmaceuticals, Llc | N,N-disubstituted aminoalkylbiphenyl antagonists of prostaglandin D2 receptors |
| EP2257536A4 (en) | 2008-02-14 | 2011-03-23 | Amira Pharmaceuticals Inc | CYCLIC DIARYL ETHERS AS ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS |
| US8497381B2 (en) | 2008-02-25 | 2013-07-30 | Panmira Pharmaceuticals, Llc | Antagonists of prostaglandin D2 receptors |
| US8426449B2 (en) | 2008-04-02 | 2013-04-23 | Panmira Pharmaceuticals, Llc | Aminoalkylphenyl antagonists of prostaglandin D2 receptors |
| MX2010014172A (es) | 2008-07-03 | 2011-02-22 | Amira Pharmaceuticals Inc | Antagonistas de receptores de prostaglandina d2. |
| JP5586606B2 (ja) * | 2008-09-02 | 2014-09-10 | アクチミス ファーマシューティカルズ インコーポレーテッド | Ｃｒｔｈ２アンタゴニストとしての同位体富化されたピリミジン−５−イル酢酸誘導体 |
| GB2463788B (en) | 2008-09-29 | 2010-12-15 | Amira Pharmaceuticals Inc | Heteroaryl antagonists of prostaglandin D2 receptors |
| WO2010039977A2 (en) | 2008-10-01 | 2010-04-08 | Amira Pharmaceuticals, Inc. | Heteroaryl antagonists of prostaglandin d2 receptors |
| US8524748B2 (en) | 2008-10-08 | 2013-09-03 | Panmira Pharmaceuticals, Llc | Heteroalkyl biphenyl antagonists of prostaglandin D2 receptors |
| GB2465062B (en) | 2008-11-06 | 2011-04-13 | Amira Pharmaceuticals Inc | Cycloalkane(B)azaindole antagonists of prostaglandin D2 receptors |
| US8383654B2 (en) | 2008-11-17 | 2013-02-26 | Panmira Pharmaceuticals, Llc | Heterocyclic antagonists of prostaglandin D2 receptors |
| BRPI0923592A2 (pt) * | 2008-12-25 | 2016-01-26 | Taisho Pharmaceutical Co Ltd | composto |
| JP2012517405A (ja) | 2009-02-09 | 2012-08-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 呼吸器及び胃腸の疾患の治療のための新規医薬組成物 |
| WO2010092043A1 (en) | 2009-02-12 | 2010-08-19 | Merck Serono S.A. | Phenoxy acetic acid derivatives |
| WO2010094643A1 (en) * | 2009-02-17 | 2010-08-26 | Glaxo Group Limited | Quinoline derivatives and their uses for rhinitis and urticaria |
| GB0908394D0 (en) | 2009-05-15 | 2009-06-24 | Univ Leuven Kath | Novel viral replication inhibitors |
| WO2011014587A2 (en) | 2009-07-31 | 2011-02-03 | Amira Pharmaceuticals, Inc. | Ophthalmic pharmaceutical compositions of dp2 receptor antagonists |
| GB0913636D0 (en) * | 2009-08-05 | 2009-09-16 | Univ Leuven Kath | Novel viral replication inhibitors |
| KR20120047273A (ko) | 2009-08-05 | 2012-05-11 | 판미라 파마슈티칼스, 엘엘씨 | Ｄｐ2 길항제 및 이의 용도 |
| JP2013512242A (ja) * | 2009-11-24 | 2013-04-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ピリミジン−５−イル酢酸誘導体のコリン塩の多形体を調製する方法 |
| MX2012007927A (es) | 2010-01-06 | 2012-08-15 | Panmira Pharmaceuticals Llc | Antagonistas de dp2 y usos del mismo. |
| ES2545865T3 (es) | 2010-01-27 | 2015-09-16 | Boehringer Ingelheim International Gmbh | Compuestos de pirazol como antagonistas de CRTH2 |
| EP2586772A4 (en) | 2010-06-23 | 2013-11-13 | Taisho Pharmaceutical Co Ltd | isoquinoline |
| CA2805452C (en) | 2010-07-05 | 2018-07-31 | Actelion Pharmaceuticals Ltd | 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators |
| JP2013535456A (ja) | 2010-07-28 | 2013-09-12 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 呼吸器系及び炎症性疾患の治療用医薬組成物 |
| JP2013535457A (ja) | 2010-07-28 | 2013-09-12 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 呼吸器系及び炎症性疾患の治療用医薬組成物 |
| KR102090990B1 (ko) | 2010-10-20 | 2020-03-19 | 에스더블유아이엠씨 엘엘씨 | 머플러 등급의 스테인리스 강을 포함하는 넓은 범위의 코팅 및 비코팅 기재에의 접착성이 향상된 수계 코팅 시스템 |
| KR20140003438A (ko) | 2010-11-15 | 2014-01-09 | 카톨리에케 유니버시테이트 루벤 | 항바이러스성 축합 헤테로사이클릭 화합물 |
| EP2457900A1 (en) | 2010-11-25 | 2012-05-30 | Almirall, S.A. | New pyrazole derivatives having CRTh2 antagonistic behaviour |
| US8759386B2 (en) | 2011-01-24 | 2014-06-24 | Boehringer Ingelheim International Gmbh | Pyrazole compounds as CRTH2 antagonists |
| JP5999387B2 (ja) | 2011-03-25 | 2016-09-28 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｒｔｈ２拮抗薬としてのピラゾール化合物 |
| JP5988253B2 (ja) | 2011-05-16 | 2016-09-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ［４，６−ビス−ジメチルアミノ−２−［４−（４−トリフルオロメチルベンゾイル−アミノ）ベンジル］ピリミジン−５−イル］酢酸の調製方法 |
| CN104114169A (zh) | 2011-12-16 | 2014-10-22 | 阿托佩斯治疗有限公司 | 用于治疗嗜酸细胞性食管炎的crth2拮抗剂和质子泵抑制剂的组合物 |
| TW201331179A (zh) | 2011-12-21 | 2013-08-01 | Actelion Pharmaceuticals Ltd | 雜環衍生物及其作為前列腺素ｄ２受體調節劑之用途 |
| EP2885307A1 (en) | 2012-07-05 | 2015-06-24 | Actelion Pharmaceuticals Ltd. | 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators |
| US20140148470A1 (en) * | 2012-11-23 | 2014-05-29 | Boehringer Ingelheim International Gmbh | Pyrimidine compounds for treating hairloss |
| TWI695831B (zh) | 2014-09-13 | 2020-06-11 | 香港商南北兄弟藥業投資有限公司 | Ｃｒｔｈ２拮抗劑化合物及其用途 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE790679A (fr) | 1971-11-03 | 1973-04-27 | Ici Ltd | Derives de l'indole |
| JPH03112985A (ja) * | 1989-09-28 | 1991-05-14 | Morishita Pharmaceut Co Ltd | Ｎ―（１ｈ―テトラゾール―５―イル）―２―フェニル―５―ピリミジンカルボキシアミド類及びその合成用中間体 |
| GB9125842D0 (en) | 1991-12-04 | 1992-02-05 | Ici Plc | Heterocyclic derivatives |
| US6326368B1 (en) * | 1996-03-27 | 2001-12-04 | Dupont Pharmaceuticals Company | Aryloxy- and arylthiosubstituted pyrimidines and triazines and derivatives thereof |
| BR9712000A (pt) * | 1996-09-06 | 1999-08-24 | Nippon Kayaku Kk | Derivados de acetamida sais dos mesmos composi-Æo farmac-utica inibidores de protease de quimase de desgranula-Æo de mastÄcitos ou de libera-Æo de histamina de mastÄcitos e de ativa-Æo de eosinÄfilo ou de libera-Æo de oxig-nio ativo de eosinÄfilo e processo para produzir os dervados de acetamida |
| JP2001302667A (ja) | 2000-04-28 | 2001-10-31 | Bayer Ag | イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体 |
| CN1239485C (zh) * | 2000-05-22 | 2006-02-01 | 里奥制药有限公司 | 作为IL－1β和TNF－α抑制剂的二苯酮类 |
| US6878522B2 (en) * | 2000-07-07 | 2005-04-12 | Baiyong Li | Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2 |
| SE0200411D0 (sv) | 2002-02-05 | 2002-02-05 | Astrazeneca Ab | Novel use |
| EP1413306A1 (en) * | 2002-10-21 | 2004-04-28 | Warner-Lambert Company LLC | Tetrahydroquinoline derivatives as CRTH2 antagonists |
| ES2401079T3 (es) | 2002-12-20 | 2013-04-16 | Amgen Inc. | Moduladores del asma y de la inflamación alérgica |
| DE60303238T2 (de) | 2003-04-25 | 2006-09-14 | Actimis Pharmaceuticals, Inc., La Jolla | Pyrimidin-Essigsäure Derivate geeignet zur Behandlung von CRTH2-bedingten Krankheiten |
| EP2170838A1 (en) | 2007-06-21 | 2010-04-07 | Actimis Pharmaceuticals, Inc., | Particulates of a crth2 antagonist |
| US8278310B2 (en) | 2007-06-21 | 2012-10-02 | Actimis Pharmaceuticals, Inc. | Amine salts of a CRTH2 antagonist |
-
2003
- 2003-04-25 DE DE60303238T patent/DE60303238T2/de not_active Expired - Lifetime
- 2003-04-25 PT PT03009384T patent/PT1471057E/pt unknown
- 2003-04-25 AT AT03009384T patent/ATE316077T1/de active
- 2003-04-25 DK DK03009384T patent/DK1471057T3/da active
- 2003-04-25 EP EP03009384A patent/EP1471057B1/en not_active Expired - Lifetime
- 2003-04-25 ES ES03009384T patent/ES2257616T3/es not_active Expired - Lifetime
-
2004
- 2004-04-01 DO DO2004000875A patent/DOP2004000875A/es unknown
- 2004-04-14 DE DE602004030907T patent/DE602004030907D1/de not_active Expired - Lifetime
- 2004-04-14 CN CN2010101716294A patent/CN101914065A/zh active Pending
- 2004-04-14 RU RU2005136655/04A patent/RU2361865C2/ru not_active IP Right Cessation
- 2004-04-14 US US10/554,668 patent/US7812160B2/en not_active Expired - Fee Related
- 2004-04-14 PL PL04727274T patent/PL1633726T3/pl unknown
- 2004-04-14 AT AT04727274T patent/ATE494279T1/de active
- 2004-04-14 MX MXPA05011399A patent/MXPA05011399A/es active IP Right Grant
- 2004-04-14 CA CA2523439A patent/CA2523439C/en not_active Expired - Fee Related
- 2004-04-14 DK DK04727274.5T patent/DK1633726T3/da active
- 2004-04-14 SI SI200431585T patent/SI1633726T1/sl unknown
- 2004-04-14 BR BRPI0409733-5A patent/BRPI0409733A/pt not_active IP Right Cessation
- 2004-04-14 EP EP04727274A patent/EP1633726B1/en not_active Expired - Lifetime
- 2004-04-14 KR KR1020057020304A patent/KR101110491B1/ko not_active Expired - Fee Related
- 2004-04-14 WO PCT/EP2004/003910 patent/WO2004096777A1/en not_active Ceased
- 2004-04-14 PT PT04727274T patent/PT1633726E/pt unknown
- 2004-04-14 JP JP2006505114A patent/JP4671955B2/ja not_active Expired - Fee Related
- 2004-04-14 CN CN2004800173378A patent/CN1809539B/zh not_active Expired - Fee Related
- 2004-04-14 ES ES04727274T patent/ES2358424T3/es not_active Expired - Lifetime
- 2004-04-14 ZA ZA200508722A patent/ZA200508722B/en unknown
- 2004-04-14 NZ NZ543693A patent/NZ543693A/en not_active IP Right Cessation
- 2004-04-14 AU AU2004233966A patent/AU2004233966B2/en not_active Ceased
- 2004-04-19 AR ARP040101311A patent/AR043885A1/es not_active Application Discontinuation
- 2004-04-21 HN HN2004000129A patent/HN2004000129A/es unknown
- 2004-04-21 GT GT200400079A patent/GT200400079A/es unknown
- 2004-04-22 MY MYPI20041479A patent/MY147984A/en unknown
- 2004-04-23 CL CL200400874A patent/CL43596B/es active
- 2004-04-23 PE PE2004000402A patent/PE20050143A1/es not_active Application Discontinuation
- 2004-04-23 TW TW093111323A patent/TWI353980B/zh not_active IP Right Cessation
- 2004-04-23 UY UY28286A patent/UY28286A1/es not_active Application Discontinuation
-
2005
- 2005-10-26 IL IL171566A patent/IL171566A/en not_active IP Right Cessation
- 2005-11-25 NO NO20055588A patent/NO20055588L/no not_active Application Discontinuation
-
2010
- 2010-08-25 US US12/868,663 patent/US7960393B2/en not_active Expired - Fee Related
- 2010-11-08 JP JP2010249273A patent/JP5161290B2/ja not_active Expired - Fee Related
-
2011
- 2011-02-03 CY CY20111100113T patent/CY1111295T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0507123A (pt) | composto, medicamento, uso de um composto, e, processo para controlar um distúrbio ou doença associadas com a atividade de crth2 no ser humano e animais | |
| TW200505873A (en) | Pyrimidine derivatives | |
| Xu et al. | Discovery and development of DNA polymerase IIIC inhibitors to treat Gram-positive infections | |
| BRPI0408682A (pt) | derivado de benzenossulfonamida, medicamento, uso do derivado de benzenossulfonamida, e, processo para controlar uma doença ou distúrbio inflamatórios ou imuno-reguladores em humanos e animais | |
| Abbate | The heart on fire: inflammasome and cardiomyopathy. | |
| CY1109790T1 (el) | Παραγωγα συντηγμενου αζολιου-πυριμιδινης | |
| BR0313460A (pt) | Derivados de naftaleno como inibidores de metaloproteinase da matriz | |
| HRP20250100T1 (hr) | Farmaceutski pripravci za liječenje cftr-posredovanih bolesti | |
| BRPI0720220B8 (pt) | derivado de quinolina, sua composição farmacêutica, seu uso, seu processo de preparação, combinação e produto compreendendo o mesmo | |
| BR112013001088A2 (pt) | "derivados substituídos como inibidores a quinase de imidazoquinolina" | |
| DE69519031T2 (de) | Neue Antibiotika und ihre enthaltende antibiotische Zusammensetzungen für die Inhibition gram positiven Bakterien und Mykoplasmen. | |
| TW200738729A (en) | Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia | |
| BR112014032581A2 (pt) | inibidores de bifluorodioxalano-amino-benzimidazol qui-nase para o tratamento de câncer, distúrbios do snc e inflamação autoimune | |
| BR112021009078A8 (pt) | Antagonistas substituídos de receptor de adenosina de aminotriazolopirimidina e aminotriazolopirazina, composições farmacêuticas e seus usos | |
| BR112021006423A2 (pt) | derivados de azitromicina e roxitromicina como fármacos senolíticos | |
| SUzUkI et al. | Trifluorothymidine exhibits potent antitumor activity via the induction of DNA double-strand breaks | |
| MX2021007192A (es) | Proceso farmaceutico e intermedios. | |
| Naik et al. | Modulation of inflammasome activity for the treatment of auto-inflammatory disorders | |
| BRPI0819976A2 (pt) | composto mimético de ácido para a inibição de isoprenil-s-cisteinil metiltransferase, composição compreedendo os mesmos, bem como uso dos ditos compostos. | |
| Gao et al. | Protein phosphatase 2C of Toxoplasma gondii interacts with human SSRP1 and negatively regulates cell apoptosis | |
| Maslov et al. | The application of arbutin in elimination resistance gramm-negative multidrug resistance bacteria of Pseudomonas aeruginosa and Enterobacter cloacea | |
| BRPI0612534A8 (pt) | derivado de quinolina como agentes antibacterianos | |
| Xia et al. | Substituted dipiperidine alcohols as potent CCR2 antagonists | |
| Ciruela et al. | Adenosine in the neurobiology of schizophrenia: potential adenosine receptor-based pharmacotherapy | |
| BR0011296A (pt) | Derivados de espiroimidazolidina, preparação dos mesmos, utilização dos mesmos e preparações farmacêuticas compreendendo os mesmos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 11A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2308 DE 31/03/2015. |